Johnson & Johnson has received FDA approval to promote Invega Sustenna as a drug that could potentially reduce the risk of incarceration for people with schizophrenia. Read more.
You might also like
Contact Our Office
Copyright 2020, Public Defender, Ninth Judicial Circuit. The material found on this web site is for informational purposes only. It should not be considered to be legal advice and is not guaranteed to be complete or up to date. Use of this web site is not intended to create, nor constitute, an attorney-client relationship. Readers should not rely upon or act upon this information without seeking professional counsel.
The Orange County Public Defender is committed to ensuring that persons with disabilities have access to its website. If the format of any material on our website is not accessible due to a disability, please e-mail PDADCoordinator@circuit9.org or call (407) 836-4806.